Article

Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin

Department of Family and Preventive Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.
Journal of the American Academy of Dermatology (Impact Factor: 5). 11/2011; 65(5 Suppl 1):S69-77. DOI: 10.1016/j.jaad.2011.04.033
Source: PubMed

ABSTRACT An estimated 750,000 melanoma survivors in the United States are at increased risk of subsequent primary cancers.
We sought to assess the risk of developing subsequent primary cancers among people with cutaneous melanoma.
Using 1992 to 2006 data from the National Cancer Institute Surveillance, Epidemiology, and End Results Program, 40,881 people with in situ melanoma and 76,041 people with invasive melanoma were followed up (mean of 5.6 years) for the development of subsequent primary cancers. The observed number of subsequent cancers was compared with those expected based on age-/race-/year-/site-specific rates in the Surveillance, Epidemiology, and End Results population. Standardized incidence ratios (SIRs) (SIR = observed number/expected number) were considered statistically significant if they differed from 1, with an alpha level of 0.05.
After a first primary in situ melanoma, risk was significantly elevated for subsequent invasive melanoma and chronic lymphocytic leukemia among men (SIRs = 8.43 and 1.44, respectively) and women (SIRs = 12.33 and 1.79, respectively). After a first primary invasive melanoma, risk was significantly elevated for subsequent invasive melanoma, thyroid cancer, non-Hodgkin lymphoma, and chronic lymphocytic leukemia among both men (SIRs = 12.50, 2.67, 1.56, and 1.57, respectively) and women (SIRs = 15.67, 1.77, 1.42, and 1.63, respectively).
Case ascertainment issues particularly affecting in situ melanoma cases could affect results. The role of detection bias in the diagnoses of some subsequent cancers cannot be completely eliminated.
The findings of the study should guide the development of strategies such as posttreatment surveillance, screening, and ultraviolet exposure education among melanoma survivors to improve cancer survivorship.

Download full-text

Full-text

Available from: Appathurai Balamurugan, Dec 16, 2013
0 Followers
 · 
120 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Skin cancer is the most common form of cancer in the United States. Melanoma skin cancer is particularly deadly; more than 8000 US residents die from it each year. Although recent reports suggest that melanoma incidence rates have been increasing, these apparent increases could be caused by an increase in reporting and/or screening, and by an actual increase in the occurrence of melanoma. In this report, we describe methods used in this supplement to assess the current burden of melanoma in the United States using data from two federal cancer surveillance programs: the Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries and the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results program. We also provide basic descriptive epidemiologic data about melanoma in the United States. Cancer incidence data from population-based cancer registries that participate in the CDC National Program of Cancer Registries and/or the NCI Surveillance, Epidemiology, and End Results Program covering 78% of the US population for 2004 to 2006 were used. Over 45 thousand melanomas were diagnosed annually, with a rate of 19 cases per 100,000 persons. Melanoma rates may vary because of differences in reporting, diagnosis, and screening. To our knowledge, the articles in this supplement constitute the first comprehensive examination of the overall burden of melanoma in the United States based on data from a majority of the US population.
    Journal of the American Academy of Dermatology 11/2011; 65(5 Suppl 1):S6-16. DOI:10.1016/j.jaad.2011.04.037 · 5.00 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several recent papers have reported standardized incidence ratios (SIRs) for second cancers after diagnosis of cutaneous malignant melanoma. This review divides the types of cancer into five types: (1) those for which UV-B (UVB) irradiance and vitamin D reduces risk; (2) those for which UVB/vitamin D reduces risk and smoking increases risk; (3) smoking related; (4) unknown UVB/vitamin D and smoking sensitivity and (5) those for which UV irradiance increases risk. For those in category 1, SIRs were either significantly elevated or not significantly different from 1.0. For those in category 2, the SIR for kidney cancer was significantly elevated, whereas the SIRs for cervical, laryngeal and rectal cancer were significantly reduced. For those in category 3, all SIRs were significantly reduced. For those in categories 4 and 5, SIRs for all types except lip cancer were significantly elevated. A registry linkage study found significantly reduced SIRs for second cancers after diagnosis of nonmelanoma skin cancer in sunny countries but found increased SIRs in less sunny countries. The SIRs for second cancer for melanoma were elevated in both sunny and less sunny countries. This review concludes that sun exposure without sufficient vitamin D production may explain the elevated SIRs for vitamin D-sensitive cancers, whereas smoking-through production of skin elastosis, thereby reducing the risk of melanoma-probably explains the findings for smoking-related cancers. Thus, guidelines on UV irradiance should emphasize regular moderate UVB irradiance rather than avoidance for those who can tan.
    01/2012; 4(1):12-7. DOI:10.4161/derm.19831
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:  Melanoma patients are at increased risk of developing a subsequent melanoma. Objectives:  To estimate risks of developing a second primary in situ or invasive cutaneous melanoma after a first melanoma, between 1989 and 2008. Methods:  Patients were followed until diagnosis of a second melanoma, date of death or end of study. Cumulative risks, standardized incidence ratio (SIR, observed second melanomas divided by background age-, calendar- and sex-specific incidence rates of melanoma, as recorded in the Netherlands Cancer Registry) and absolute excess risk (AER, observed minus expected per 10 000 person-years) of second melanomas were calculated. Results:  In total, 10 765 in situ and 46 700 invasive melanoma patients were included. Cumulative risks of a second invasive melanoma after a first in situ or invasive melanoma at 20 years of follow-up were 6.2% and 5.0%, respectively. Relative risk of developing any melanoma (in situ or invasive) after any first melanoma (SIR) was 12.4 [invasive after invasive melanoma; 95% Confidence Interval(CI) = 11.6-13.2] to 26.4 [in situ after in situ melanoma; 95% CI = 22.6-30.7] fold increased compared to the general population. SIRs and AERs remained elevated up to 20 years after the first melanoma. Conclusons:  This study shows significantly increased long-term risks (both relative and absolute) of developing a second invasive melanoma after a first melanoma (invasive and in situ) which might serve as a basis for follow-up guidelines.
    British Journal of Dermatology 07/2012; DOI:10.1111/j.1365-2133.2012.11123.x · 4.10 Impact Factor